Developing and getting approved an antibody drug conjugate against cancer boils down to getting the right ADC formula comprising a targeted tumor, linker and payload, and VelosBio's CEO David Johnson says he and his team believe they have identified those components and that investors showed similar belief by backing the Seattle-based biotech's recent $58m Series A funding round.
VelosBio Inc. describes itself as a next generation oncology company which is developing antibody drug conjugates to target solid...